Clinical Trial

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-11; most recent amendment 2026-06-04.
Status change: Not Yet Recruiting → Recruiting 2026-04-10
Trial Details
NCT Number NCT07227818
Lead Sponsor Neurocrine Biosciences
Conditions Schizophrenia
Enrollment 560 participants
Start Date 2025-12-16
Primary Completion 2029-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-05